

PATENT

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

14772 U.S. PRO
10/607521
06/26/03



Mail Stop Patent Application
Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: DEAV2002/0044US NP

INVENTORS: Stefan Schäfer, et al

TITLE: Use of Vasopeptidase Inhibitors in the Treatment of Metabolic Diseases, Nephropathy and Advanced Glycation End-Product Associated Diseases

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

6-26-03
Date of Deposit

Bonnie Stein
Signature

EV 069262006 US
Express Mail No.

APPLICATION ELEMENTS

1. *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. Specification
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (*if filed*)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure

Total Pages 38
3. Drawing(s) (35 U.S.C. 113)

Total Sheets 1
4. Oath or Declaration
 - a. Newly unexecuted (original or copy)

b. Copy from a prior application (37 CFR § 1.63(d))
 - i. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).

Total Pages 2
5. Power of Attorney

Total Pages

 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR § 1.63(d))
6. Microfiche Computer Program (*Appendix*)

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. Computer Readable Copy
 - b. Paper Copy (identical to computer copy)
 - c. Statement verifying identity of above copies

If a CONTINUING Application, check appropriate box, and supply the requisite information:

Continuation Divisional Continuation-in-part

of prior application no: _____, filed _____,

Examiner _____, Group/Art Unit _____.

(The cross reference has been/will be inserted on page one of the specification).

This application claims priority from German Application No. 10229180.2-41, filed June 28, 2002 and claims the benefit of U.S. Provisional Application No. 60/423,590, filed November 4, 2002.

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.


ACCOMPANYING APPLICATION PARTS

- 7. Assignment Papers (*cover sheet & document(s)*)
- 8. 37 CFR §3.73(b) Statement
(when there is an assignee)
- 9. Verified English Translation Document (*if applicable*)
- 10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
- 11. Preliminary Amendment
- 12. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- 13. *Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
- 14. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- 15. Other: Application Data Sheet

CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label





Lawrence L. Martin, Reg. No. 46,902
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4803
Telefax (908) 231-2626
Aventis Docket No. DEAV2002/0044US NP

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

for FY 2003

Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$ 930.00)**Complete if Known**

Application Number	T Be Assigned
Filing Date	Filed Concurrently Herewith
First Named Inventor	Stefan Schaf r, t al
Examiner Name	T Be Assigned
Group / Art Unit	T Be Assigned
Attorney Docket No.	DEAV2002/0044US NP

METHOD OF PAYMENT (check all that apply)
 Check Credit Card Money Order Other None
 Deposit Account

Deposit Account Number	18-1982
------------------------	---------

Aventis Pharmaceuticals Inc.

The Commissioner is authorized to: (check all that apply)

- Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account

FEE CALCULATION**1. BASIC FILING FEE**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee Code	Fee (\$)	Fee (\$)
1001	2001	750	750
1002	2002	330	165
1003	2003	520	260
1004	2004	750	375
1005	2005	160	80
SUBTOTAL (1)		(\$750)	

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	30	-20** = 10	x 18 = 180
Independent	3	- 3** = 0	x 84 = 0
Claims			
Multiple Dependent			=

Large Entity	Small Entity	Fee Description
Fee Code	Fee Code	Fee (\$)
1202	2202	18 9
1201	2201	84 42
1203	2203	280 140
1204	2204	84 42
1205	2205	18 9
SUBTOTAL (2)		(\$180.00)

*or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee Code	Fee (\$)	Fee (\$)
1051	2051	130 65	Surcharge - late filing fee or oath Surcharge - late provisional filing fee or cover sheet
1052	2052	50 25	Non-English Specification
1053	2053	130 130	For filing a request for reexamination
1812	1812	2,520 2,520	Requesting publication of SIR prior to Examiner action
1804	1804	920* 920*	Requesting publication of SIR after Examiner action
1805	1805	1,840* 1,840*	Extension for reply within first month
1251	2251	110 55	Extension for reply within second month
1252	2252	410 205	Extension for reply within third month
1253	2253	930 465	Extension for reply within fourth month
1254	2254	1,450 725	Extension for reply within fifth month
1255	2255	1970 985	Notice of Appeal
1401	2401	320 160	Filing a brief in support of an appeal
1402	2402	320 160	Request for oral hearing
1403	2403	280 140	Petition to institute a public use proceeding
1451	1451	1,510 1,510	Petition to revive - unavoidable
1452	2452	110 55	Petition to revive - unintentional
1453	2453	1,300 650	Utility issue fee (or reissue)
1501	2501	1,300 650	Design issue fee
1502	2502	470 235	Plant issue fee
1503	2503	630 315	Petitions to the Commissioner
1460	1460	130 130	Petitions related to provisional applications
1807	1807	50 50	Submission of Information Disclosure Stmt
1806	1806	180 180	Recording each patent assignment per property (times number of properties)
8021	8021	40 40	Filing a submission after final rejection (37 CFR § 1.129(a))
1809	2809	750 375	For each additional invention to be examined (37 CFR § 1.129(b))
1810	2810	750 375	Request for Continued Examination (RCE)
1801	2801	750 375	Request for expedited examination of a design application
Other fee (specify)			

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**SUBMITTED BY**

Complete (If applicable)

Name (Print/Type)	Lawrence L. Martin, Reg. No. 46,902	Registration No. (Attorney/Agent)	46,902	Telephone	(908) 231-4803
Signature				Date	6/26/2003

WARNING: Information in this form may become public. Credit card information should not be included in this form. Provide credit card information and authorization in PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template